While prostate cancer is a detectable disease, more than 60% of men remain unscreened. Current standards are failing patients, physicians, health systems, and payors.
PSA tests and biopsies are inaccurate, invasive, and often result in overtreatment in their attempt to detect the presence of the disease or predict the likelihood that a future biopsy will indicate the presence of high-risk cancer.